Article Sidebar
Published:
Apr 19, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Prognostic value of serum stimulating thyroglobulin in metastatic radioactive iodine refractory differentiated thyroid cancer
Abstract
Purpose: To investigate the prognostic value of serum-stimulated thyroglobulin (ps-Tg) before the first 131I therapy in patients with metastatic radioactive iodine-refractory differentiated thyroid cancer (RR-DTC).
Methods: From August 2017 to August 2020, the clinical data for 160 patients with thyroid papillary carcinoma (PTC) who received thyroidectomy and 131I treatment were analyzed retrospectively. Differences in clinical data and related thyroid indices were compared. Univariate and multivariate logistic regression analyses were used to analyze the related factors affecting the occurrence of RR-DTC. Receiver-operator characteristic (ROC) curves were used to determine the discriminative power of ps-Tg in predicting RR-DTC, while the Kaplan-Meier survival curve of ps-Tg for RR-DTC was drawn.
Results: A total of 160 patients with thyroid cancer were enrolled, including 47 males, and 113 females (70.62 %). Overall mean age was 39 ± 13 years old. The follow-up results showed that 68 patients with thyroid cancer were refractory to radioactive iodine. The ps-Tg of the iodine-refractory group was higher than that of the iodine-receptive group (p < 0.001). Multivariate logistic regression showed that ps-Tg was an independent risk factor for RR-DTC (OR = 1.086, p = 0.000). The optimal cut-off value of ps-Tg for predicting progression to RR-DTC was 19.21 μg/L. Kaplan-Meier survival curve showed that the risk of iodine refractory in patients with thyroid cancer (≥ 19.21 μg/L) was higher than that of patients with thyroid cancer < 19.21 μg/L (p < 0.001).
Conclusion: The ps-Tg before the first 131I therapy independently predicts the occurrence of metastatic RR-DTC when ps-Tg is greater than the risk of RR-DTC increase. This finding will be helpful in predicting the occurrence of RR-DTC, in order to determine the best time to start treatment and make individualized treatment decisions.
